Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
The body processes and eliminates the peptide quickly rather than building up concentrations over time
The company has also developed Mounjaro (tirzepatide) as the follow-up product of Trulicity
doi: 10.3390/nu16070963
Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats
US$ 26.40
US$ 22.65
US$ 22.83
US$ 23.43
US$ 23.89
